{"id":10428,"date":"2024-10-30T07:24:50","date_gmt":"2024-10-30T12:24:50","guid":{"rendered":"https:\/\/ibio.org\/?p=10428"},"modified":"2024-10-30T07:24:50","modified_gmt":"2024-10-30T12:24:50","slug":"chicagos-pathos-ai-raises-62m-to-advance-ai-driven-drug-development","status":"publish","type":"post","link":"https:\/\/ibio.org\/chicagos-pathos-ai-raises-62m-to-advance-ai-driven-drug-development\/","title":{"rendered":"Chicago&#8217;s Pathos AI Raises $62M to Advance AI-Driven Drug Development"},"content":{"rendered":"<p class=\"whitespace-pre-wrap break-words\">Pathos AI, a Chicago-based biotech startup, has secured $62 million in Series C funding to advance its AI-driven approach to drug development, according to a Tuesday <a href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/29\/2970762\/0\/en\/Pathos-AI-Closes-62M-Oversubscribed-Series-C-Round-of-Financing-to-Accelerate-its-Platform-Approach-to-Drug-Development.html\">press release<\/a>. The funding news, also covered by Katherine Davis of <a href=\"https:\/\/www.chicagobusiness.com\/health-care\/tempus-execs-biotech-startup-pathos-ai-raises-62m\">Crain&#8217;s Chicago Business<\/a> and Kyle LaHucik of <a href=\"https:\/\/endpts.com\/pathos-ai-nabs-62m-series-c-as-it-hunts-for-more-phase-1-drugs-with-ai\/\">EndPoints News<\/a>, revealed that the round was led by New Enterprise Associates with participation from Revolution Growth, valuing the company at $600 million and bringing its total funding to $102 million.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">Unlike traditional AI drug discovery companies, Pathos AI focuses on identifying existing Phase 1 cancer drugs that could succeed with more targeted patient populations. The company uses artificial intelligence to determine which patients are most likely to respond to specific treatments.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">&#8220;By leveraging AI to understand why some patients respond and others do not, we believe we can materially increase the probability of successful trials,&#8221; said Ryan Fukushima, Interim CEO of Pathos AI, who also serves as chief operating officer of Tempus.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">The three-year-old company, founded by Tempus executives including CEO Eric Lefkofsky, has already acquired three clinical-stage drugs through deals with Prelude Therapeutics, Rain Oncology, and Novo Nordisk. Pathos AI plans to launch new clinical trials for these medicines in 2025.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">The funding will support the expansion of the company&#8217;s scientific team and further development of its PathOS\u2122 Platform, which uses AI to improve patient selection strategies and clinical trial design.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pathos AI, a Chicago-based biotech startup, has secured $62 million in Series C funding to advance its AI-driven approach to drug development, according to a Tuesday press release. The funding news, also covered by Katherine Davis of Crain&#8217;s Chicago Business and Kyle LaHucik of EndPoints News, revealed that the round was led by New Enterprise [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":10430,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[145,526],"tags":[489,660,485],"class_list":["post-10428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community-news","category-newsbrief","tag-ai","tag-pathos-ai","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=10428"}],"version-history":[{"count":1,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10428\/revisions"}],"predecessor-version":[{"id":10429,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10428\/revisions\/10429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/10430"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=10428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=10428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=10428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}